S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
NASDAQ:ZIOP

ZIOPHARM Oncology - ZIOP Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.82
▼
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ZIOP stock logo

About ZIOPHARM Oncology (NASDAQ:ZIOP) Stock

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Stock News Headlines

February 23, 2023 | finance.yahoo.com
USA Community Oncology Services Market Competitor Scenario - Market Positioning And Player-Based Strategies, By The Business Research Company
February 18, 2023 | finance.yahoo.com
Verdi Oncology's Horizon Oncology Announces Agreement with Integra Connect to Bring Value-Based Care to Central Indiana
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
February 18, 2023 | marketwatch.com
Global Gene Therapy in Oncology Market Size is Booming Across the Globe and Witness Huge Growth by Key Players to 2030 By VMReports
February 18, 2023 | seekingalpha.com
iBio shares more than double in value after hours on new immuno-oncology target program
January 24, 2023 | marketwatch.com
Cancer Care Market is booming in near Future 2023-2028
January 13, 2023 | finanznachrichten.de
Nerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset
January 5, 2023 | thestreet.com
Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
November 26, 2022 | marketwatch.com
Cancer Care Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries Data
November 12, 2022 | finance.yahoo.com
Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor
October 20, 2022 | finance.yahoo.com
Gadeta Appoints Scientific Advisory Board and Provides Business Update
September 27, 2022 | marketwatch.com
Global Cancer Care Market Size and Scope 2022 Research Report by Consumption, Revenue, Regions, Gross Margin and Forecast to 2026
September 24, 2022 | finanznachrichten.de
Celyad Oncology SA: Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
September 7, 2022 | finance.yahoo.com
Candel Therapeutics Announces Two Executive Leadership Appointments
September 2, 2022 | thestreet.com
Why This Fund Manager Is Short Ziopharm
August 25, 2022 | thestreet.com
Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta
August 22, 2022 | finance.yahoo.com
Global Allogeneic Cell Therapy Market Size-Forecasts to 2027
August 18, 2022 | fool.com
ZIOPHARM Oncology (NASDAQ: ZIOP)
August 9, 2022 | sg.finance.yahoo.com
North America oncology market value to cross USD 246 billion by 2028
August 3, 2022 | marketwatch.com
Testicular Cancer Drugs Market is Booming Right Now, let's Understand Market Size, Share and Forecast till 2028
July 15, 2022 | marketwatch.com
Gene Therapies for Cancer Treatment Market to Garner Considerable Growth at a higher % of CAGR During the Study Period 2022-2028
July 15, 2022 | marketwatch.com
Testicular Cancer Drugs Market Size 2022 Report by Industrial Growth, Share, Emerging Trends, Latest Development, Segmentations and Forecast to 2028
June 1, 2022 | finance.yahoo.com
CellChorus Announces Scientific Advisory Board
May 4, 2022 | nasdaq.com
What Makes Ziopharm (TCRT) a New Buy Stock
April 26, 2022 | finance.yahoo.com
Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer
March 3, 2022 | finance.yahoo.com
Immuno-oncology Cell Therapy Market worth $34.69 Billion by 2030 - Exclusive Report by InsightAce Analytic
See More Headlines
Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Company Calendar

Last Earnings
11/08/2021
Today
3/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ZIOP
CUSIP
98973P10
CIK
1107421
Web
www.ziopharm.com
Phone
(617) 259-1970
Fax
617-241-2855
Employees
105
Year Founded
2005

Profitability

EPS (Most Recent Fiscal Year)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,980,000.00
Net Margins
N/A
Pretax Margin
-22,544.97%
Return on Equity
-92.84%
Return on Assets
-72.46%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
3.43
Quick Ratio
3.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
216,146,000
Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links


Key Executives

  • Kevin S. BoyleKevin S. Boyle
    Chief Executive Officer & Director
  • Timothy M. Cunningham
    Chief Financial Officer
  • Lynn M. Ferrucci
    EVP-Human Resources, Administration & IT
  • Raffaele Baffa
    Chief Medical Officer & Head-Research
  • Eleanor M. de Groot
    General Manager-Cell Therapy & Executive VP

Key Competitors

View All Competitors













ZIOP Stock - Frequently Asked Questions

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. During the same period in the previous year, the company earned ($0.10) earnings per share.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology (NASDAQ:ZIOP) has a market capitalization of $0.00. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

The company employs 105 workers across the globe.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The official website for the company is www.ziopharm.com. The biotechnology company can be reached via phone at (617) 259-1970, via email at dconnolly@ziopharm.com, or via fax at 617-241-2855.

This page (NASDAQ:ZIOP) was last updated on 3/21/2023 by MarketBeat.com Staff